Login to Your Account

Bug battle venture Vir enlists Scangos, draws more than $150M

By Michael Fitzhugh
Staff Writer

Friday, January 6, 2017

Vir Biotechnology Inc., a new enterprise pursuing infectious disease therapies with immunology ideas popularized by cancer fighters, is launching under the leadership of departing Biogen Inc. CEO George Scangos.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription